Impact of Obesity on Influenza A Virus Pathogenesis, Immune Response, and Evolution

Rebekah Honce\textsuperscript{1,2} and Stacey Schultz-Cherry\textsuperscript{*}

\textsuperscript{1}Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN, United States, \textsuperscript{2}Integrated Program in Biomedical Sciences, Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, United States

With the rising prevalence of obesity has come an increasing awareness of its impact on communicable disease. As a consequence of the 2009 H1N1 influenza A virus pandemic, obesity was identified for the first time as a risk factor for increased disease severity and mortality in infected individuals. Over-nutrition that results in obesity causes a chronic state of meta-inflammation with systemic implications for immunity. Obese hosts exhibit delayed and blunted antiviral responses to influenza virus infection, and they experience poor recovery from the disease. Furthermore, the efficacy of antivirals and vaccines is reduced in this population and obesity may also play a role in altering the viral life cycle, thus complementing the already weakened immune response and leading to severe pathogenesis. Case studies and basic research in human cohorts and animal models have highlighted the prolonged viral shed in the obese host, as well as a microenvironment that permits the emergence of virulent minor variants. This review focuses on influenza A virus pathogenesis in the obese host, and on the impact of obesity on the antiviral response, viral shed, and viral evolution. We comprehensively analyze the recent literature on how and why viral pathogenesis is altered in the obese host along with the impact of the altered host and pathogenic state on viral evolutionary dynamics in multiple models. Finally, we summarized the effectiveness of current vaccines and antivirals in this populations and the questions that remain to be answered. If current trends continue, nearly 50% of the worldwide population is projected to be obese by 2050. This population will have a growing impact on both non-communicable and communicable diseases and may affect global evolutionary trends of influenza virus.

Keywords: influenza, obesity, pathogenesis, evolution, immunity

INTRODUCTION

Obesity rates have nearly tripled worldwide since 1975. Approximately 1.9 billion people are overweight and over 650 million are obese, defined as having a body mass index (BMI) of 25 to 30 and >30, respectively, which translates to nearly 45% of adults worldwide (1, 2). The obesity-induced inflammatory state has systemic implications for individual and global public health. It is a well-identified risk factor for increased mortality due to heightened rates of heart disease, certain cancers, and musculoskeletal disorders (3). Overnutrition, as well as undernutrition, has been cited as an important factor in the body’s response to infection for...
centuries (4–6). More recently, the impact of obesity on communicable diseases has been appreciated. During the 2009 influenza A virus (IAV) H1N1 pandemic, a plethora of epidemiologic studies revealed obesity to be an independent risk factor for severe disease (7, 8). In initial retrospective studies of laboratory-confirmed H1N1 cases after the 2009 pandemic, obesity was identified as a risk factor for hospitalization, the need for mechanical ventilation, and mortality upon infection (9–11).

Influenza is a potentially severe respiratory infection caused by the influenza virus. Most human cases are caused by H1N1 and H3N2 IAV strains (12, 13). Several case studies of severe and fatal IAV infections have identified possible effects of obesity on disease progression; these effects include extensive viral replication in the deep lung, progression to viral pneumonia, and prolonged and increased viral shedding (14–16). However, these studies neglected to determine the causality between obesity and severe IAV pathogenesis. Studies in mouse models of obesity, including leptin-deficient (OB) and leptin-receptor-deficient (DB) genetically obese models as well as the high-fat diet-induced-obese (DIO) model (Table 1) have identified several immunological mechanisms for the increased pathogenesis and mortality that mirrors what has been seen in humans (26–29). Advances in obese ferret models and human primary cell culture are enabling better translational studies of the mechanisms behind the increased disease severity, viral life cycle alterations, and evolutionary dynamics due to the obesogenic environment (30). In this review, we analyze the current literature for information on the impact of obesity on influenza virus pathogenesis, the immune responses to the virus and the transmission dynamics of IAV including viral shedding and evolution.

**PATHOGENESIS AND RESOLUTION OF IAV INFECTION**

IAV infection is characterized by fever, myalgia, rhinorrhea, sore throat and sneezing. Symptoms peak 3–5 days post infection (p.i.), with viral shedding peaking at day 2–3 p.i. (31). Most human IAV infections are limited to the upper respiratory tract, including the nasal, tracheal and often bronchial epithelium. In more severe cases, there is infection of the lower respiratory tract (LRT) including the lung occurs, often with severe sequelae requiring hospitalization (32). Development of viral pneumonia and secondary bacterial infections can lead to acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and eventual death (32). Progression of the infection to the LRT and severe sequelae are more common in the obese population, leading to poorer infection resolution and recovery than is seen in non-obese patients.

**Lung Pathology and Infection Outcomes**

After the 2009 H1N1 pandemic, retrospective studies across the globe found obesity to be comorbid with influenza in nearly one-third of hospitalized patients as well as in fatal cases (33–35). In both pandemic and non-pandemic influenza seasons, obesity increased the risk of hospitalization for laboratory-confirmed IAV infection, with increasing BMI increasing the odds ratios (36, 37). The susceptibility extended to heightened disease severity, with obese children and adults experiencing increased morbidity and mortality during LRT infections, including comorbid secondary infections and a risk of ARDS (38, 39). Obesity was shown to increase both the length of stay in intensive care and the need for mechanical ventilation (40). Most strikingly, severe obesity resulted in a two-times greater risk of death upon IAV infection and hospitalization due to the infection, with moderate obesity also increasing the risks (41, 42). In other high-risk populations such as pregnant and post-partum women, obesity further increased the risk of IAV infection (43).

Upon infection with IAV, the viral replication process as well as the pro-inflammatory, antiviral immune response, damages the respiratory epithelium and recovery requires proper clearance and remodeling of the damaged surfaces. Increased lung damage, pulmonary edema, cellularity, inflammatory response, and immunopathology is evident in DIO and OB mice as compared to wild-type (WT) mice inoculated with IAV in both naive and vaccine challenge experiments (26, 27, 44–48). The few comparative studies for which no difference in lung pathology was reported used relatively high lethal doses, highlighting the importance of taking into account the viral stock preparation and the means of administration when comparing host responses and pathogenesis (49).

In severe cases, IAV infection can cause a break-down of the respiratory epithelium, leading to fluid influx to the airway space (32). Obese mice are more likely than are lean (LN) mice to have increased lung permeability during infection. Using Evan’s blue dye, Karlsson et al. found that at day 7 p.i., OB mice showed a significantly greater increase in permeability when compared to LN mice (48). This finding was confirmed by the increased albumin levels in bronchoalveolar lavage fluid (BALF) at days 5–8 p.i., in both OB and DIO mice, showing that there is increased protein leakage from the lung into the BALF (27, 48, 50). The increased lung permeability is coupled with an increase in lung edema and oxidative stress upon IAV infection, emphasizing the multiple etiologies of increased lung pathology in the obese host (27, 46, 49). Infection resolution requires the repair of the damaged epithelial surface, but OB and DIO hosts are impaired in wound repair (27). Reduced cellular proliferation as determined through decreased KI-67 staining is evident in OB and DIO mouse lung sections at days 6 and 14 p.i. leaving the lung susceptible to secondary infections and eventual ARDS (27).

The heightened immunopathology and poor wound recovery in OB and DIO mice result in increased mortality. IAV strains H3N2 and H1N1 induce greater mortality in OB and DIO mice than in WT C57BL/6 mice, regardless of their respective vaccine histories (26, 27, 47, 50). This is also true for a viral-bacterial co-infection model. DIO and OB mice inoculated with PR8 IAV, CA/09 IAV, seasonal H3N2 virus, or influenza B virus and challenged with *Streptococcus pneumoniae* at day 7 post influenza infection had increased mortality when compared to controls (48).
Viral Load and Spread in Respiratory Epithelia

The increased incidence of ALI and ARDS in hospitalized obese patients may be due to increased viral spread to the LRT and alveolar region, thus resulting in impaired lung function and gas exchange (38). Limited case studies that list obesity as a comorbidity reference heightened viral replication and extensive hemorrhage in the alveoli leading to increased disease severity (16, 51). Continued investigation using ex vivo human systems as well as following naturally occurring infections in cohorts of obese and lean patients can help determine how the data gleaned from mouse models translates to human infection, as well as how other comorbidities such as metabolic syndrome, chronic disease, age, and gender will affect the pathogenesis of IAV (3, 52, 53).

Although some studies have demonstrated higher viral titers in obese mice than in non-obese animals, others have found no such difference (27, 44). In a viral-bacterial co-infection model, there was no difference in the influenza viral load between obese and WT mice at peak disease, but obese mice had higher viral titers at later timepoints when compared to WT controls (48). Similarly, the viral titers in OB and DIO mice infected with H1N1 viruses were no different to the titers in WT mice at peak infection at days 3 and 6 p.i., but the obese mice had prolonged infections (27, 54). Titration of the virus in lung homogenates showed that WT animals had undetectable levels of virus by day 10 p.i. whereas OB mice showed no discernable decrease in viral titer (54). Conversely, some reports have suggested that DIO mice have higher viral titers early in infection with no change at later timepoints post-infection (44, 49). The disparities between these reports may be due to differences in the inoculation method, dose, heterogeneity of influenza viral strains, or viral stock preparations. Nevertheless, OB mice experience worse outcomes after infection independent of increased viral titers.

Obese mice exhibit increased viral spread to the LRT. More viral antigen was present in the bronchiolar and alveolar regions in DIO mice inoculated with H1N1 virus than in the corresponding regions of infected control animals (55). In the viral-bacterial co-infection model, OB mice inoculated with a fluorescent reporter virus showed increased viral spread in the nasopharynx, trachea, and lung at day 8 and 9 p.i., as determined through live-animal imaging, along with more extensive areas of active viral infection at days 7 and 9 p.i., as determined by nucleoprotein staining of sectioned lung tissue (48). Excised lungs from OB mice showed this increased viral spread to be present as early as day 3 p.i. (54). The culmination of severe lung pathology and increased viral spread leads to increased mortality in obese mice due to influenza infection and severe sequelae (27).

Systemic immune deficits and obesity-related poor pulmonary mechanics contribute to the observed increased susceptibility of obese hosts to IAV (56); however, ex vivo studies with primary human respiratory epithelial cells have revealed intrinsic cellular differences in viral replication in obese and lean subjects (57, 58). In limited studies with alveolar epithelial cells (AECs), Huang et al. showed that H7N9 infection of obese-derived cells resulted in a greater increase in viral RNA production from 24 to 72 h post infection (h.p.i.) than was seen in infected of lean-derived cells (58). These results support the limited data demonstrating that obese AECs are more susceptible to infection (57). Further studies are warranted to elucidate the mechanism behind this increased susceptibility at the epithelial cell level.

HOST ANTIVIRAL RESPONSE TO INFLUENZA INFECTION

Obesity results in a dampened immune response to infectious agents, leading to poorer outcomes post-infection (3, 28, 59). Systemic alterations to antiviral immunity, including both the innate and adaptive responses, have been described for IAV infection of the respiratory epithelium (Figure 1). Baseline alterations in the obese lung environment affect the viral pathogenesis and immune response and leave the lung susceptible to increased viral spread and secondary infections due to the poor induction of antiviral immunity.

Innate Immunity

Non-specific and quick-acting innate immune defenses provide the initial host response to IAV in the lung epithelium (61). An altered chemokine and cytokine milieu is characteristic of obese hosts and contributes to the meta-inflammation seen in this population (62, 63). Increased visceral and omental adiposity results in an efflux of pro-inflammatory cytokines that influence systemic cellular processes (56, 64–66). The baseline and post-IAV infection chemokine and cytokine alterations in mouse models of obesity are outlined in Table 2.

### Table 1 | Description of commonly used mouse models of obesity.

| Model                  | ID  | Genetics                                                                 | Weighta | Diet and behavior                              | References |
|------------------------|-----|--------------------------------------------------------------------------|---------|-----------------------------------------------|------------|
| Genetic leptin knockout| OB  | Most commonly on C57BL/6 background; spontaneous recessive, homozygous Lep<sup>ob</sup> nonsense mutation | 45 g    | Normal chow; hyperphagic due to loss of appetite control and satiety | (17, 18)  |
| Genetic leptin receptor knockout | DB  | Commonly on C57BL/Ks or C57BL/6j backgrounds; spontaneous mutant in Lep<sup>ob</sup> allele causing abnormal splicing | 40 g    | Normal chow; hyperphagic due to loss of leptin receptor signal transduction | (19, 20)  |
| Diet-induced           | DIO | Any background, commonly C57BL/6j; some strains more susceptible than others | 35 g    | High-fat diet; exhibits typical eating patterns | (21–25)   |
| Control                | LNWT| Any matched genetic background                                           | 25 g    | Either low-fat diet (LN) or regular chow; diet choice may alter results | (21, 25)  |

*aTypical weight in grams for an 8-week-old male.
In DIO and OB mice, baseline alterations in systemic and localized chemokines and cytokines results from increased visceral and omental adiposity (66, 73). The adipose tissue of OB and DIO mice produces heightened levels of several adipokines including MCP-1, TNF-α, and IL-6, as well as the cytokine transforming growth factor-β (TGF-β), all of which have systemic impacts (64, 66, 74). Two key adipokines that are intimately tied to obese status are leptin and adiponectin (75–77). Higher serum leptin and lower adiponectin levels due to obesity may contribute to the heightened pro-inflammatory cytokine production, as well as to the poor responsiveness to infection stimuli in DIO mice (78). Early in IAV infection of DIO mice, the expression of IL-6, TNFα, and type I interferons (IFNs) is delayed and reduced compared to that in LN mice, and differential regulation of IL-2 and IL-12 is detected in lung homogenates, whereas later in infection there is increased inflammation in DIO mice as compared to LN mice later in infection (26, 55, 64). This is converse to the baseline state in the lungs of obese mice, which is characterized by high expression of pro-inflammatory cytokines and chemokines (44). Differential regulation of the antiviral cytokines and IFN response upon IAV infection in obese mice may contribute to the poor adaptive responses as discussed below (26, 55, 71).

Obese adult humans, like mouse models, have elevated circulating pro-inflammatory cytokines as well as increased leptin and reduced adiponectin levels, leading to a systemic leptin-resistance and effects on the baseline immune status (79, 80). Fewer studies have investigated the innate antiviral responses. In studies with primary human epithelial cells, cells from obese individuals displayed a smaller change in the levels of IL-8, IL-1β, and IP-10 levels at 72 h.p.i., which is consistent with the delayed and blunted cytokine response seen in obese rodent models (58). Future studies should continue to explore the epithelial-specific responses to influenza infection in primary cells of lean and obese individuals, as the respiratory epithelium is the primary site of influenza infection and replication.

Systemic alterations in cytokine levels upon infection may be due to upregulated expression of suppressor of cytokine signaling (SOCS) proteins. SOCS proteins are involved in the negative regulation of JAK-STAT signaling and in the induction of type I and type III IFNs and pro-inflammatory cytokines (81–83). In DIO mice, there is upregulated expression of SOCS1 and SOCS3 mRNA expression in the lungs (78). Similar upregulation of SOCS expression has been seen in PBMCs isolated from lean and obese humans. Reduced type I IFN production from toll-like receptor (TLR)-stimulated PBMCs was concordant with SOCS3 overexpression in cells derived from obese subjects (84). Overexpression of SOCS3 and SOCS1 proteins was evident at baseline in PBMCs from obese subjects, but stimulation with TLR3 and TLR7 specific agonists caused no concordant increase in expression as is typical in cells derived from lean individuals (85). These alterations may be tied to leptin resistance, as leptin uses downstream signal transduction pathways similar to those for antiviral chemokines and cytokines (86, 87). Changes in lipids...
and lipid-derived mediators also affect the response to IAV in obese hosts. The impact of obesity on the lung metabolome contributes to the increased severity of IAV disease in DIO mice, which may be ameliorated through exogenous administration of statins and acetaminophen (88, 89).

Antigen Presentation and Phagocytosis
The bridge between non-specific innate immunity and antigen-specific adaptive immunity relies on appropriate actions of immune cells from both the lymphoid and myeloid lineages (90). There are more leukocytes in the lungs of DIO mice than in those of WT mice (91). Various effects of obesity on these leukocyte subpopulations including macrophages, dendritic cells, natural killer (NK) cells, and neutrophils have been described and the reports are often contradictory (28, 61, 92, 93). Here, we will focus on influenza-specific investigations and on the functional changes in these immune cells in the respiratory system (Table 3).

The systemic pro-inflammatory state of the obese host extends to the lung microenvironment. Macrophages collected from bone marrow and blood of OB and DIO mice show a polarization toward an M1 pro-inflammatory phenotype (91, 96). This is compounded by the impaired migration of macrophages to lung alveoli during infection, which could lead to poor clearance of the invading pathogen (46, 91). In DIO and OB mice, lung resident alveolar macrophages are reduced in number as a result of infection, and those that remain show a reduction in the expression of type I IFN receptor and in IFN-stimulated gene expression when compared to WT mice (26, 54). These changes may be due in part to the obesity-related chronic inflammation, as a chronically inflamed mouse model shows similarly reduced macrophage activation and blunt pro-inflammatory cytokine production upon macrophage stimulation (97).

The poor vaccine response that is characteristic of the obese host (and is further discussed below) may be partially due to suboptimal macrophage functionality and maturation. Although phagocytosis is increased in peritoneal macrophages isolated from DIO mice, macrophages derived from obese individuals show reduced activation as measured by CD86 expression before and after stimulation ex vivo, impairing their ability to activate effector cells of the immune system (98). This finding is further supported by the increased presence of immature monocytes but equal presence of effector alveolar and interstitial macrophages in BALF collected from DB mice at day 4 p.i (69). Continued studies of the physiologic function of lung-resident and migratory macrophages will increase our understanding of the mechanism behind poor induction of the immune and vaccine response.

Dendritic cells (DCs) prime the T cell response of the immune system through presentation of phagocytosed antigens. Several studies have shown that the phagocytic function and activation of DCs and other antigen presenting cells remain sufficient in the obese host (29, 99), whereas another study suggests that the overall number of DCs and antigen presentation is impaired in DCs from lungs of DIO mice (71). The authors of the latter study argue that the reduction in antigen presentation by DCs fails to instruct the T cell response and is related to the elevated IL-6-driven pro-inflammatory state of the DIO mouse lung (71).

Further studies have shown that in OB and DIO mice, poorly activated DCs fail to induce T cell proliferation, possibly because similar pro-inflammatory signals blunt their maturation (66, 100, 101). In human cohorts, obese patients have reduced number of circulating DCs and those remaining are less responsive to ex vivo stimulation with TLR agonists than are those of non-obese patients; however, further studies are needed to discern whether this observation extends to IAV infection (102).

Neutrophils also show a pro-inflammatory N1 phenotype in DIO mice, and those from obese humans show increased production of inflammatory free radicals upon stimulation ex vivo (80, 91). Lethally challenging DIO mice with PR8 virus results in the production of more neutrophil extracellular traps than are seen in LN mice, and an increase in neutrophil migration is seen at day 3 p.i. in the lungs of OB mice, at days 6 and 14 p.i. in OB and DIO mice, and at day 4 p.i. in the DB BALF (27, 49, 69). This may compound the severity of the observed lung pathology as a result of the increased release of cytotoxic proteins and the development of ALI (27, 46, 103). Conversely, NK cells are decreased in DIO mice as well as in overweight and obese humans but increased in OB mice (26, 102, 104, 105). Malnutrition has been empirically shown to increase the severity of IAV disease and impair NK cell function in WT mice, yet DIO and OB mice show increased NK cell infiltration of the lung at days 6 and 14 p.i., whereas DB mice show a decrease in NK cells in the BALF at day 4 p.i. (27, 69, 106). No studies have investigated the impact of obesity on the response of basophils, eosinophils, and other leukocytes during IAV infection. However, as obesity causes perturbation in the circulating leptin and adiponectin levels, leading to a state of leptin-resistance, and leptin can interact with signal transduction pathways critical to the aforementioned leukocytes and other immune cells, the impact of the obesogenic environment may extend beyond our current knowledge (87).

Adaptive Immune Responses
Once primed by the earlier innate response, lymphocytes of the adaptive arm of the immune system can continue the control and clearance of IAV, leading to the resolution of the infection, however, obesity dampens and delays these processes (28, 107). Both T cell and B cell responses show reduced efficacy in the obese host, impairing the resolution of IAV infection.

T Cells
T cell lymphopenia as well as reduced proliferation, activation, and function of T cells has been described in DB and OB mice (78, 100, 108). One study with a small sample size found no changes in DIO mouse T cell proliferation and cytokine production upon stimulation ex vivo (98). Recent studies have aimed to clarify the literature and to elucidate the molecular mechanism behind the reduced T cell response seen in both obese mice and humans, as well as how specific T cell subsets respond to the obese environment and IAV infection.

Deficiencies in the activation and function of CD4+ and CD8+ T cells were found in studies performed with PBMCs isolated from healthy weight, overweight, and obese humans (29, 109). After ex vivo stimulation with H1N1 virus, CD8+, and CD4+ T cells derived from obese
| Analyte | Model | Effect at baseline | Effect during infection | References |
|---------|-------|--------------------|-------------------------|------------|
| TGFβ   | DIO   | ↓ Lung concentration; ↑ lung mRNA expression; ↑ BALF concentration | ↓ Lung concentration | (27, 67) |
| TNFα   | DIO   | ↑ Plasma concentration; ↑ lung mRNA expression; ↑ BALF concentration | ↑ BALF concentration at 8 dpi; delayed lung mRNA expression ↑ at 3 and 6 dpi; delayed BALF concentration 3 and 8 dpi; ↓ lung concentration fold increase at 1 and 3 dpi; ↑ circulating concentration fold increase at 3 dpi | (26, 46, 55, 67–70) |
| G-CSF  | DIO   | ↑ Lung concentration | ↑ BALF concentration at 4 dpi | (27, 70) |
| IL-1β  | DIO   | ↓ Lung mRNA expression at 3 dpi; ↓ BALF concentration at 3 dpi | ↓ Lung mRNA expression at 3 dpi; ↓ BALF concentration at 3 dpi; ↓ lung concentration fold increase at 1 and 3 dpi; ↑ lung concentration from baseline at 3 dpi | (55, 70–72) |
| IL-2   | DIO   | ↓ LN mRNA expression at 3 and 7 dpi | ↓ LN mRNA expression at 3 and 7 dpi | (26) |
| IL-5   | DIO   | ↓ BALF concentration at 3 dpi | ↓ BALF concentration at 3 dpi | (70) |
| IL-6   | DIO   | Fewer macrophages producing ↑ at 3 dpi; delayed lung mRNA expression at 3 and 6 dpi, delayed BALF concentration ↑ at 3 and 8 dpi, ↑ lung and serum concentration at 4 dpi | ↓ Lung mRNA expression at 3 and 8 dpi; delayed BALF concentration 3 and 8 dpi; delayed lung mRNA expression at 3 and 6 dpi; delayed BALF concentration 3 and 8 dpi; ↑ circulating concentration from baseline at 3 dpi | (26, 70–72) |
| IL-12  | DIO   | ↓ LN mRNA expression at 3 and 7 dpi | ↓ LN mRNA expression at 3 and 7 dpi | (71) |
| IL-12p70 | DIO | ↓ BALF concentration at 3 dpi | ↓ BALF concentration at 3 dpi | (70) |
| IL-13  | DIO   | Delayed BALF concentration at 3 and 8 dpi | Delayed BALF concentration at 3 and 8 dpi | (70) |
| Leptin | DIO   | ↑ Serum concentration; ↑ lung mRNA expression | ↑ Serum concentration ↑ at 2, 4, and 6 dpi; ↑ circulating concentration fold increase at 3 dpi | (26, 44, 55, 67, 72) |
| Adiponectin | DIO | ↓ Serum concentration; ↓ lung mRNA expression | ↓ Serum concentration at 2 and 6 dpi; ↓ circulating concentration fold increase at 3 dpi | (26, 67, 72) |
| CXCL1/KC | DIO | ↑ Plasma concentration | ↑ BALF concentration at 8 dpi | (46, 50, 68) |
| CXCL2/MIP2α | DIO | ↑ Plasma concentration | ↑ BALF concentration at 8 dpi; ↑ BALF concentration increase at 8 dpi | (68, 72) |
| CXCL10/IP-10 | DIO | ↑ Plasma concentration | ↓ Lung mRNA expression at 1 dpi; delayed BALF ↑ concentration at 3 and 8 dpi | (68, 70) |
| CCL2/MCP-1 | DIO | ↑ Plasma concentration | ↑ BALF concentration at 8 dpi; ↓ lung mRNA expression at 3 dpi | (46, 71) |
| CCL3/MIP1α | DIO | ↓ BALF concentration at 3 dpi; ↑ lung concentration at 4 dpi | ↑ BALF concentration at 3 dpi; ↑ lung concentration at 4 dpi | (70, 72) |
| CCL5/RANTES | DIO | ↑ Plasma concentration | Delayed lung mRNA expression at 3 and 6 dpi; ↓ BALF concentration at 3 and 6 dpi | (68, 70, 72) |
| CCL7/MCP3 | DIO | ↑ Plasma concentration | Delayed lung mRNA expression at 3 and 6 dpi; ↓ BALF concentration at 3 and 6 dpi | (68) |
| CCL11/Eotaxin | DIO | | Delayed BALF concentration 3 and at 8 dpi | (70) |
| IFNα   | DIO   | ↓ Lung mRNA expression at 2 dpi | ↓ Lung mRNA expression at 2 dpi | (26) |
| IFNβ   | DIO   | ↓ Lung mRNA expression at 2 and 3 dpi | ↓ Lung mRNA expression at 2 and 3 dpi | (26) |
| IFNγ   | DIO   | ↑ Circulating concentration fold increase at 3 dpi | ↑ Circulating concentration fold increase at 3 dpi | (54, 70) |
| Ilr7   | OB    | ↓ Alveolar macrophage mRNA expression | ↓ Alveolar macrophage mRNA expression at 1 dpi; ↓ lung mRNA expression fold-increase at 1 dpi | (54, 70) |
| Oas1a  | DIO   | ↓ Lung mRNA expression fold-increase at 1 dpi | ↓ Lung mRNA expression fold-increase at 1 dpi | (70) |
| Oas1g  | OB    | ↓ Alveolar macrophage mRNA expression; ↓ epithelial cell mRNA expression | ↓ Alveolar macrophage mRNA expression at 1 dpi | (54) |
| Ifit1  | OB    | ↓ Alveolar macrophage mRNA expression | ↓ Alveolar macrophage mRNA expression at 1 dpi | (54) |
| Mx2    | DIO   | ↓ Lung mRNA expression fold-increase at 1 dpi | ↓ Lung mRNA expression fold-increase at 1 dpi | (70) |

↑ increased, ↓ decreased, LN, lymph node; BALF, bronchial alveolar lavage fluid. Fold increase is measured as the fold increase from baseline of uninfected obese mice; delayed increase in expression or concentration relates to a delayed increase from baseline as compared to the immune response in matched WT mice.
TABLE 3 | Immune cell subsets in the obese lung environment at baseline and during influenza infection in murine models of obesity.

| Cell type              | Model     | Impact at baseline                                      | Impact during infection                                                                 | References |
|------------------------|-----------|---------------------------------------------------------|----------------------------------------------------------------------------------------|------------|
| Monocytes              | DIO       | ↑ BALF infiltration at 3, 4, 6, and 14 dpi              | ↓ BALF infiltration at 3, 6, and 14 dpi                                                | (27)       |
|                        | OB        | ↑ BALF infiltration at 3 dpi                            | ↓ BALF infiltration at 4 dpi                                                           | (48)       |
|                        | DB        | ↑ M1 polarization; ↓ CD86+ and activation; ↓ migration to lung | ↓ BALF infiltration at 4 dpi                                                           | (46)       |
| Macrophages            | DIO       | ↓ Type I IFN receptor signaling                         | ↓ IFN mRNA expression; ↓ IFNAR signaling; Δ Numbers in BALF at 4 dpi; Δ Numbers in BALF at 7 dpi | (46, 48)   |
| Alveolar Macrophages   | OB        | ↑ BALF number                                           | Δ Numbers in BALF at 3 dpi                                                             | (26, 27, 46) |
| Interstitial Macrophages| DIO      | Δ Lung number                                           | ↑ BALF infiltration at 16 and 14 dpi; ↓ BALF infiltration at 4 dpi                     |            |
| Natural Killer cells   | DIO       | Δ Lung number                                           | ↑ BALF infiltration at 6 and 14 dpi; ↓ BALF infiltration at 4 dpi; Δ BALF infiltration at 4 dpi |            |
|                        | OB        | Δ Lung number                                           | ↑ BALF infiltration at 6 and 14 dpi; ↓ BALF infiltration at 4 dpi; Δ BALF infiltration at 4 dpi |            |
|                        | DB        | Δ BALF infiltration at 4 dpi                            | → BALF infiltration at 4 dpi                                                           |            |
| Dendritic cells        | DIO       | ↓ Antigen presentation; ↓ Induction of T cell proliferation; ↓ lung DC and pDC number at 3 dpi; ↑ LN migration |                                                                                       | (71)       |
| Neutrophils            | DIO       | ↑ N1 polarization                                       | ↑ NET production; ↑ BALF infiltration at 6 and 14 dpi                                  | (27, 48, 49) |
|                        | OB        | ↑ BALF infiltration at 3, 6, and 14 dpi; ↓ BALF infiltration at 7 dpi |                                                                                       |            |
|                        | DB        | ↑ BALF infiltration at 4 dpi                            | → BALF infiltration at 4 dpi                                                           |            |
| B cells                | DIO       | ↑ Circulating IgG; ↓ mature bone marrow B cells; ↓ cross-reactive H1N1 and PR8 antibodies at 5, 8, and 14 dpi |                                                                                       | (50, 94)   |
| T cells                | CD8+      | ↑ OCR:ECAR ratios                                       | ↓ Lung at 7 dpi; ↑ cross-reactive CD8+ cells at 5 dpi                                 | (46, 50, 68, 71, 78, 95) |
|                        | DIO       | ↑ OCR:ECAR ratios                                       | ↓ Lung at 5 dpi in heterologous challenge; ↓ lung at 3, 4 dpi, and 84 dpi; ↓ BALF at 8 dpi |            |
|                        | DB        | ↑ OCR:ECAR ratios                                       | ↓ Lung at 5 dpi in heterologous challenge; ↓ lung at 3, 4 dpi, and 84 dpi; ↓ BALF at 8 dpi |            |
| T<sub>REG</sub>        | ↑ Lung numbers                                   | Δ Primary T<sub>MEM</sub> at 30 dpi; ↑ and T<sub>CM</sub> at 5 dpi in heterologous challenge; ↓ T<sub>MEM</sub> at 3 and 7 dpi; ↓ T<sub>REG</sub> suppression of lean T<sub>MEM</sub> |            |
| T<sub>MEM</sub>        |           |                                                         |                                                                                       |            |

↑ Increased, ↓ decreased, Δ no change/equal; BALF, bronchoalveolar lavage fluid; DN DC, double negative dendritic cell; pDC, plasmacytoid dendritic cell; T<sub>REG</sub>, regulatory T cell; T<sub>MEM</sub>, memory T cells; T<sub>CM</sub>, central memory T cell; T<sub>EM</sub>, effector memory T cell.

Subjects produced significantly more IL-5, whereas IFN-γ production trended lower, compared to T cells derived from healthy weight subjects. Compared to participants of healthy weight, obese participants had a smaller percentage increase in the production of IFN-γ from activated T cells, whereas overweight and obese participants had a smaller increase in granzyme B-producing T cells. Significantly lower fold increases in TNEO and trends toward lower fold increases in IL-6 were also described in these participants.

Interrogations of specific T cell subsets found no difference in the levels of β δ T cells due to obesity; however, γδ T cells were reduced in number, and those remaining showed increased differentiation that impaired their antiviral functionality and response to antigen presentation. Decreasing levels of γδ T cells correlates with increasing obesity status, and the remaining γδ T cells possess an immature phenotype characterized by poor IFN-γ production concordant with γδ T cells from an aged host. The antiviral function of γδ T cells is regulated by type I IFNs, and the lack of an IFN response in the OB host could explain their poor functionality. The poor T cell responses to influenza could also be due to reduced T cell diversity, as in DIO mice obesity accelerated the reduction in T cell receptor excision circles, leading to the reduction of T cell Vβ repertoire diversity which parallels what is seen in the aged host. These findings are commensurate with the “adipaging” hypothesis, whereby obese status accelerates the aging of the immune system to mirror the immune deficits seen in elderly people.

Obesity-related metabolic dysregulation has been proposed as the driver of poor effector T cell and helper T cell function as well as impaired memory T cell responses and vaccine efficacy, as it may alter T cell metabolism. In their study, Rebeles et al. initially inoculated DIO or LN mice with X-31 influenza virus, then challenged DIO, LN, or weight loss diet-switched DIO mice with PR8 influenza virus. T cells isolated from DIO and LN mice were tested for glycolysis as measured by their extracellular acidification rate (ECAR) as well as mitochondrial respiration as measured via their oxygen consumption rate (OCR). A high OCR:ECAR ratio suggests a greater relative magnitude of oxidative phosphorylation vs. glycolysis, which is an indicator of a naïve or memory T cell phenotype as opposed to the glycolytic phenotype of effector T cells.
In DIO mice, as well as in DIO mice after weight loss, the OCR:ECAR ratios were elevated for both CD4+ and CD8+ T cells on day 7 of a secondary infection, showing that obesity alters the metabolic programming of memory T cells and that this change is maintained even after weight loss (95). It has been suggested that the differential cytokine milieu and growth factor deficiency blunt the maturation of antigen presenting cells, thereby extending the poor innate response seen in obese hosts to later adaptive responses. Exogenous application of IL-2 was also shown to improve the γδ T cell response, and a lack of this cytokine was suggested to impair dendritic cell antigen presentation (71, 99).

B Cells
Few studies have investigated how the obesogenic state affects humoral responses to IAV infection. The increased visceral adiposity due to obesity attracts increased B cell numbers, thus contributing to systemic, chronic inflammation through interactions with T cells (116, 117). Stimulated human B cells ex vivo secreted less IL-6, but increased IgM levels correlated with obesity state (94). However, the literature on how these baseline alterations affect the IAV-specific response is sparse.

During IAV infection, DIO mice have lower levels of H1N1-specific antibodies and a reduced neutralizing response when compared to LN mice, which is mirrored upon vaccination and subsequent homologous or heterologous challenge (44, 50). In DIO mice, un-stimulated B cells showed elevated IgG and IgM levels ex vivo (94). Hemagglutination inhibition (HAI) titers measured at days 7 and 21 p.i. with H1N1 virus in DIO mice were less than those in LN mice. This reduction in titer was related to a decrease in B cells in the bone marrow of DIO mice as well as to diminished specific B cell subsets (94). A single report has suggested that suggests antibody-dependent-cellular cytotoxicity (ADCC) is slightly increased in OB mice; however, no further studies have defined ADCC in the context of IAV infection (104).

To date, no studies have determined how obesity affects the response of other facets of humoral immunity, including germinal center formation, class-switching of antibodies, and the Fc receptor repertoire, to IAV infection. In other models of infection in the obese host, reduced IgG class switching but elevated IgM levels followed bacterial infection (118). DIO mice showed reduced formation of lymph node associated germinal centers and reduced recruitment of T cells and B cells to these germinal centers at day 14 p.i. (118). As leptin is a major regulator of B cell development, maturation, and activity, alterations to the adipokine balance due to obesity may directly affect B cell function, B cell interactions with other lymphoid cell types such as T-follicular helper cells, and antibody class-switching (72, 87).

INFLUENZA VIRAL EVOLUTION IN THE OBESE HOST

Recent studies have aimed to identify not only the mechanisms by which IAV affects the obese host, but also how the obesogenic state may directly affect IAV itself. RNA viruses, with their short generation times and error-prone replication, exhibit a quasispecies population comprising viral variants that collectively increase viral fitness in the host (119). Nutritional status has been implicated in altering within-host viral evolution and has been shown to prolong infections, delay clearance, and increased shedding, all of which potentially increase viral transmission (120, 121).

Clearance, Shedding, and Transmission
Obese patients hospitalized with severe IAV disease have higher peak viral loads and a delayed clearance when compared to non-obese patients (122, 123). Two studies have extended the findings in obese mouse models to humans by identifying high BMI as increasing the duration and quantity of IAV shedding. Maier et al. found that viral shedding is prolonged in obese adults. In their cohort of adults in Managua, Nicaragua, IAV shedding in symptomatic obese adults lasted 42% longer than in symptomatic lean counterparts. In obese adults with no symptoms or only a single symptom of active IAV infection, virus shedding lasted 104% longer than in lean adults with similar symptoms (124). No association between BMI and duration of viral shedding was found for children or adolescents, or with influenza B virus (124). In a study of college-aged adults in Maryland, USA, Yan et al. quantified viral RNA in aerosols from collected breath and found that it correlated positively with BMI, which also suggests that there is increased viral load and viral shedding in obese humans (125).

Several studies have shown that WT animals clear IAV infection earlier than do OB (48, 54). In the DB model, clearance of IAV was impaired in global leptin receptor knockout mice but not in lung epithelium conditional knockout animals. This suggests that a global loss of the leptin receptor impairs viral clearance, possibly through immune cell-mediated interactions with the respiratory epithelium (69). Both epithelial dysregulation and perturbations of immune cells are observed in human and mouse obesity and may impair the elimination of IAV from the respiratory tract.

Evolution and Population Dynamics
Host nutritional status has long been known to impact viral pathogenesis and more recently, to impact viral populations (126). However, evolutionary dynamics of IAV infection within a single host, whether human, animal models, or reservoirs, is an emerging field (127). The extended infections and increased shed seen in obese human cohorts provides ample reason to investigate how the obese host may alter IAV evolution and population dynamics (Figure 2) (124, 125).

In a study with both OB and DIO mice, we discovered the obesity promotes the emergence of virulent variants within the IAV population. We showed that inoculating naïve WT mice with viruses that had been serially passaged through OB mice resulted in enhanced morbidity compared to that in mice inoculated with virus passed through LN or WT mice or with the parental virus. The increased virulence of the serially passaged viruses was related to point mutations in the polymerase segments and NS1, as well as to increased population-wide diversity for OB-derived
viruses. This increased virulence in WT animals was observed within two rounds of passage in the obese mice, suggesting that the population changes occur rapidly. Similar passaging experiments with seasonal H3N2 virus yielded equivalent results, as the parental virus was unable to productively infect WT mice, yet the OB-passaged virus could infect and cause severe morbidity in WT mice. Furthermore, IAV propagated in normal human bronchial epithelial (NHBE) cells derived from OB donors replicated to higher titers upon inoculation of MDCK cells and caused more cell death when compared to viruses grown in NHBE cells from average-weight donors. These findings raise concerns that even a single infection of an OB host may result in an altered viral population, leading to heightened virulence properties or transmission that can affect the global evolution of IAV (127).

RNA viruses such as IAV rely on an error-prone RNA-dependent RNA polymerase; this provides a fitness advantage to the viral quasispecies by enabling the emergence of minor viral variants (119, 128). The analysis of infections with multiple variants, the rate of reassortment, and the within-host evolutionary dynamics are areas in which the impact of obesity must be defined. The increased viral spread but similar viral load observed in obese hosts as compared to lean hosts may highlight how infection of different cell types or the individual viral load within single cells can impact the cooperative and competitive dynamics within the quasispecies (127, 129). The advent of single-cell technologies and improvements in deep sequencing will usher in a new understanding of the complex interactions between host cell and IAV in lean and obese individuals (129, 130). The appearance of IAV minor variants within the individual host is concordant with the eventual emergence of the same variants in global circulation, and the impact of obesity on the rise of potentially pathogenic viral variants in the human host is an urgent need for study (127). Furthermore, certain variants may contribute to antiviral resistance, vaccine escape, and/or enhanced transmission, and the increasing prevalence of obesity will undoubtedly affect these evolutionary dynamics (127, 128, 131).

PHARMACOLOGICAL CONTROL OF INFLUENZA VIRUS INFECTION

Vaccination before seasonal outbreaks and prompt antiviral administration during infection are key to controlling IAV infection. The poor initial and adaptive responses to natural infection and vaccination set up an impaired ability to respond adequately to a secondary challenge. Vaccine efficacy may be decreased in obese humans, who will then rely on prompt antiviral administration to control viral infection (Figure 3). However, more studies are warranted to better understand how the obese state affects the control of infection.

Prevention of Infection Through Vaccination

Studies of vaccine efficacy in human cohorts have shown that initial seroconversion rates are high in the obese population, but that there is a greater decline in vaccine efficacy over time than is seen in non-obese populations (132). In one study of elementary school-age children, obesity was linked to increased cough and more school days being missed. However, vaccination was equally protective for obese and non-obese children (133). Another study of adults vaccinated with the trivalent influenza vaccine found that increased BMI was associated with a reduction in the protective immune response over time (110). Although individuals with a high BMI had an initially higher fold increase in IgG antibodies and HAI titers, by 12 months post-vaccination there was a greater decline in antibody titers in obese participants than in non-obese participants (110, 134). Similar trends were seen in a childhood cohort, with the mean HAI titers against both H1N1 and type B influenza viruses being elevated overweight and obese patients (135). However, as is noted by Neidich et al. our current correlates of protection may not be predictive of actual protection from infection and may explain why vaccinated obese adults display adequate HAI titers but still succumb to IAV infection at higher rates than healthy-weight adults (132). Clearly, more studies are warranted on the population wide efficacy and waning of protection of the influenza vaccine, as well as the impact of obesity on vaccine-induced immunity.
Increased lung pathology (titers as well as quicker waning of protective antibody levels and increased lung pathology) in DIO mice (78). However, other studies in the DIO model have observed a reduction in memory T cell numbers several months post-infection in DIO mice (78). This reduction in memory T cells may result in a lower immune response against influenza.

FUTURE STUDIES

The definition of the obese lung microenvironment and systemic alterations in the cytokine milieu continue to be refined, thereby advancing studies on how to ameliorate disease severity in the obese host. Meliopoulos et al. showed that the β6 integrin is an important regulator of the type I IFN response in the lung, in addition to controlling viral spread and post-infection wound recovery. OB and β6 integrin double knockout mice were partially protected from severe infection, showed reduced viral spread, and displayed restored levels of IFN production.
and signaling (54). Interventions such as weight loss programs, diet change, and exercise are the first-line of defense against the obesity epidemic, yet few studies have examined whether these interventions will improve antiviral outcomes in obese patients. Studies have found no change in cellular immunity against influenza upon weight loss in DIO mice; however, nutritional supplementation may be warranted as the administration of essential fatty acids may increase the B cell response to IAV (94, 95). Exercise improves the obese host response to IAV in the obese host, restoring levels of IAV-specific IgG antibodies, CD8+ T cells, ciliary beat frequency, IFNα gene expression and cytokine production in the BALF of DIO mice to mirror a metabolically healthy state (70). These results provide evidence that nutritional, exercise, and medical interventions may improve the collective immune response, but they highlight the continued need for development of potent antivirals and vaccines.

Continued studies of the mechanistic interactions between the lung epithelia, resident and circulating immune cells, and influenza virus will aid in the understanding of influenza pathogenesis and, potentially, in the development of novel therapeutics for obese and other high-risk populations. Modeling the collective knowledge assembled from obese mouse models, ex vivo human systems, and studies conducted in human cohorts may help generate new hypotheses to explain the increased disease severity and reduced immune response in obese humans. By bridging work done in virology, immunology, physiology, and metabolism, researchers can gain a holistic view of how obesity affects everything from the systemic immune response to localized events in the viral life cycle within respiratory epithelial cells.

CONCLUSION

Overall, the baseline inflammatory obese state presents a barrier to the induction of a robust antiviral response. Innate and adaptive immune responses are delayed or blurred, allowing increased viral spread and extended infections in the obese host. Immunopathologic responses late in infection additionally undermine the host response, and in synergy with uncontrolled viral replication and spread, they lead to poor—often lethal—outcomes. Even when IAV infections have been cleared, the increased susceptibility to secondary bacterial infections and poor healing of the lung epithelium contribute to the high mortality rates in the obese populations. Furthermore, within the obese host influenza virus may exploit the lack of antiviral pressure, generate a more virulent population and augment disease severity, even displaying increased virulence upon subsequent infection of a lean environment.

The extent to which these findings can be extrapolated to other respiratory viruses remains unclear. The continued refinement of human primary cell cultures and the translational obese ferret model will enable a greater mechanistic understand of the impact of obesity on influenza pathogenesis, the host response, and the evolutionary dynamics of the virus (30). The growing prevalence of obesity is alarming, as infection of an obese host may soon be the standard pathogenesis, instead of the well-characterized infection of a healthy-weight host. With increasing infections in the obese host, so too may the incidence of severe influenza pandemics increase as a result of increased viral shedding, and transmission and the emergence of novel viral variants. Curbing the obesity epidemic will not only improve the quality of life for those millions of people directly affected; it will also dampen the impact of obesity on infectious disease.

AUTHOR CONTRIBUTIONS

RH performed the literature search, wrote and edited the drafts, created figures, and contributed to manuscript revision and submission. SS-C secured funding, provided supervision, edited the final draft, and contributed to manuscript revision and submission.

FUNDING

Funding was provided by ALSAC and NIAID HHSN272201400006C.

ACKNOWLEDGMENTS

The authors thank Keith A. Laycock, Ph.D., ELS, for scientific editing of the manuscript.

REFERENCES

1. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. (2015) 313:1973–4. doi: 10.1001/jama.2015.4260
2. WHO. Obesity and Overweight [Online]. World Health Organization (2019). Available online at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed April 26, 2019).
3. Andersen CJ, Murphy KE, Fernandez ML. Impact of obesity and metabolic syndrome on immunity. Adv Nutr. (2016) 7:66–75. doi: 10.3945/an.115.010207
4. Underwood M. A Treatise on the Diseases of Children: With General Directions for the Management of Infants from the Birth. Philadelphia, PA: Thomas Dobson (1789).

5. Flanigan CC, Sprunt DH. The effect of malnutrition on the susceptibility of the host to viral infection. J Exp Med. (1956) 104:687–796.
6. Webb SR, Loria RM, Madge GE, Kibrick S. Susceptibility of mice to group B coxsackie virus is influenced by the diabetic gene. J Exp Med. (1976) 143:1239–48.
7. Van Kerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med. (2011) 8:e1001053. doi: 10.1371/journal.pmed.1001053
8. Sun Y, Wang Q, Yang G, Lin C, Zhang Y, Yang P. Weight and prognosis for influenza A(H1N1)pdm09 infection during the pandemic period between 2009 and 2011: a systematic review of observational studies with meta-analysis. Infect Dis. (2016) 48:813–22. doi: 10.1080/23744235.2016.1201721
9. Vaillant L, La Ruche V, Tarantola A, Barboza P, Epidemic Intelligence Team at InVS. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill. (2009) 14:19309.

doi: 10.2807/eu.14.19309-en

10. Venkata C, Sampathkumar P, Afessa B. Hospitalized patients with 2009 H1N1 influenza infection in the Mayo Clinic experience. Mayo Clin Proc. (2010) 85:798–805.

doi: 10.4065/mcp.2010.10166

11. Thompson DL, Jungk J, Hancock C, Smelser C, Landen M, Nichols M, et al. Risk factors for 2009 pandemic influenza A (H1N1)-related hospitalization and death among racial/ethnic groups in New Mexico. Am J Public Health. (2011) 101:1776–84.

doi: 10.2105/aph.2011.300223

12. Collaborators GB. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. (2015) 386:743–800.

doi: 10.1016/S0140-6736(15)60692-4

13. WHO. Seasonal Influenza [Online]. World Health Organization (2018). Available online at: http://www.who.int/mediacentre/factsheets/fs211/en/ (accessed April 26, 2019).

14. Gerberding JL, Morgan JG, Shepard J, Kradin RL. Case reports of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 9-2004. An 18-year-old man with respiratory symptoms and shock. N Engl J Med. (2004) 350:1256–47.

doi: 10.1056/NEJMcp0 30906

15. Fleury H, Burrel S, Balick Weber C, Hadrien R, Blanco P, Cazanne C, et al. Prolonged shedding of influenza A(H1N1)v virus: two case reports from France 2009. Euro Surveill. (2009) 14:49.

doi: 10.2807/eu.14.19434-en

16. Nakajima N, Hata S, Sato Y, Tobiume M, Kato H, Kaneko K, et al. The first autopsy case of pandemic influenza (A/H1N1pdm) virus infection in Japan: detection of a high copy number of the virus in type II alveolar epithelial cells by pathological and virological examination. Jpn J Infect Dis. (2010) 63:67–71. Available online at: http://www.nih.go.jp/it/ JJID/63/67.html

17. Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse. J Hered. (1950) 41:317–8.

18. Lindström P. The physiology of obese hyperglycemic mice [ob/ob Mice]. Sci World J. (2007) 7:666–85.

doi: 10.1100/sw.2007.117

19. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia. (1978) 14:141–8.

20. Collin GB, Maddatu TP, Sen S, Naggert JK. Genetic modifiers interact with Cpe(fat) to affect body weight, adiposity, and hyperglycemia. Physiol Genomics. (2005) 22:182–90.

doi: 10.1152/physiogenomics.00208.2003

21. Hariri N, Thibault L. High-fat diet-induced obesity in animal models. Nutr Rev. (2010) 23:270–99.

doi: 10.1111/j.0029-6624.2009.00168.x

22. Sims EK, Hatanaka M, Morris DL, Tersey SA, Kono T, Chaudry ZZ, et al. Divergent compensatory responses to high-fat diet between C57BL/6/J and C57BLKS/J inbred mouse strains. J Physiol Endocrinol Metabol. (2013) 305:E1495–1511.

doi: 10.1152/ajpendo.00366.2013

23. Williams LM, Campbell FM, Drew JE, Koch C, Hoggard N, Rees WD, et al. Impaired wound healing predisposes obese mice to severe influenza virus infection. J Infect Dis. (2012) 205:252–61.

doi: 10.1093/infdis/jir729

24. Mancuso P. Obesity and respiratory infections: does excess adiposity weigh down host defense? Pulm Pharmacol Ther. (2013) 26:412–9.

doi: 10.1016/j.pupt.2012.04.006

25. Paech HA, Sheridan PA, Handy J, Karlsson EA, Schultz-Cherry S, Hudgens MG, et al. Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza A virus. Obesity. (2013) 21:2377–86.

doi: 10.1002/oby.20383

26. Rebeles J, Dhungana S, Stewart DA, Sumner SC, Meyer S, et al. Obesity Increases mortality and modulates the lung metabolome in a mouse model. J Infect Dis. (2012) 205:244–51.

doi: 10.1093/infdis/jir731

27. Karlsson EA, Herzog T, Johnson C, Melamed L, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. (2008) 167:775–85.

doi: 10.1093/aje/kwm375

28. Albrecht RA, Liu WC, Sant AJ, Tompkins SM, Pekosz A, Meliopoulos V, et al. Moving forward: recent developments for the ferret biomedical research model. MBio. (2018) 9:18.

doi: 10.1128/mBio.01113-18

29. Carrat F, Vergu E, Ferguson NM, Lemaitre C, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. (2008) 167:775–85.

doi: 10.1093/aje/kwm375

30. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol. (2008) 3:499–522.

doi: 10.1146/annurev.pathmechdis.3.121806.154316

31. Bassetti M, Parisi S, Calti A, Pallavicini FM, Cassola G, Artioli S, et al. Risk factors for severe complications of the novel influenza A (H1N1): an analysis of patients hospitalized in Italy. Clin Microbiol Infect. (2011) 17:247–50.

doi: 10.1111/j.1469-0691.2010.03275.x

32. Albrecht RA, Liu WC, Sant AJ, Tompkins SM, Pekosz A, Meliopoulos V, et al. Moving forward: recent developments for the ferret biomedical research model. MBio. (2018) 9:18.

doi: 10.1128/mBio.01113-18

33. Paech HA, Sheridan PA, Handy J, Karlsson EA, Schultz-Cherry S, Hudgens MG, et al. Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza A virus. Obesity. (2013) 21:2377–86.

doi: 10.1002/oby.20383
vaccination leads to severe secondary bacterial infection during influenza virus-infected obese mice. *MBio*. (2017) 8:17. doi: 10.1128/mBio.00889-17

49. Moorthy AN, Tan KB, Wang S, Narasaraju T, Chow VT. Effect of high-fat diet on the formation of pulmonary neutrophil extracellular traps during influenza pneumonia in BALB/c Mice. *Front Immunol*. (2016) 7:289. doi: 10.3389/fimmu.2016.00289

50. Milner JJ, Sheridan PA, Karlsson EA, Schultz-Cherry S, Shi Q, Beck MA. Diet-induced obese mice exhibit altered heterologous immunity during a secondary 2009 pandemic H1N1 infection. *J Immunol*. (2013) 191:2474–85. doi: 10.4049/jimmunol.1202429

51. Yokoyama T, Tsushima K, Ushiki A, Kobayashi N, Urushihata K, Kozumi T, et al. Acute lung injury with alveolar hemorrhage due to a novel swine-origin influenza A (H1N1) virus. *Intern Med*. (2010) 49:427–30. doi: 10.2169/internalmedicine.49.3022

52. Huang PL. A comprehensive definition for metabolic syndrome. *Dis Model Mech*. (2009) 2:231–7. doi: 10.1242/demm.001180

53. Perez LM, Pareja-Galeano H, Sanchez-Gomar F, Emanuele E, Lucia A, Galvez BG. “Adipaging”: ageing and obesity share biological hallmarks related to a dysfunctional adipose tissue. *J Physiol*. (2016) 594:3187–207. doi: 10.1113/JP21691

54. Meliopoulos V, Livingston B, Van de Velde LA, Honce R, Schultz-Cherry S. Absence of beta6 integrin reduces influenza disease severity in highly susceptible obese mice. *J Virol*. (2018) 93:e01646–18. doi: 10.1128/JVI.01646-18

55. Easterbrook JD, Dunfee RL, Schwartzman LM, Jagger BW, Sandouk A, Kash JC, et al. Obese mice have increased morbidity and mortality compared to non-obese mice during infection with the 2009 pandemic H1N1 influenza virus. *Influenza Other Respir Viruses*. (2011) 5:418–25. doi: 10.1111/j.1750-2699.2011.00254.x

56. Dixon AE, Peters U. The effect of obesity on lung function. *Exp Rev Respir Med*. (2012) 18:755–67. doi: 10.1586/17476348.2012.1506331

57. Travanty E, Zhou B, Zhang H, Di YP, Alcorn JF, Wentworth DE, et al. Differential susceptibilities of human lung primary cells to H1N1 Influenza Viruses. *J Virol*. (2015) 89:11955–44. doi: 10.1128/JVI.01792-15

58. Huang CG, Lee LA, Wu YC, Hsiou MJ, Horng JT, Kuo RL, et al. A pilot study on primary cultures of human respiratory tract epithelial cells to predict patients’ responses to H7N9 infection. *OncoTarget*. (2018) 9:14492–508. doi: 10.18632/oncotarget.24537

59. Nieman DC, Henson DA, Nehlsen-Cannarella SL, Eikens M, Uter AC, Butterworth DE, et al. Influence of obesity on immune function. *J Am Diet Assoc*. (1999) 99:294–9. doi: 10.1016/S0002-8223(99)00077-2

60. Karlsson EA, Beck MA. The burden of obesity on infectious disease. *Nat Rev Microbiol*. (2010) 12:755–67. doi: 10.1038/nrmicro3262

61. Shah D, Romero F, Duong M, Wang N, Paudyal B, Suratt BT, et al. Obesity-induced adipokine imbalance impairs mouse pulmonary vascular endothelial function and primes the lung for injury. *Sci. Rep*. (2015) 5:11362. doi: 10.1038/srep11362

62. Hamilton BS, Paglia D, Kwan AY, Chan CC, et al. Leptin mediates the pathogenesis of severe 2009 pandemic influenza A(H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity. *J Infect Dis*. (2013) 207:1270–80. doi: 10.1093/infdis/jit031

63. Samad F, Yamamoto K, Pandey M, Loskutoff DJ. Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. *Mol Med*. (1997) 3:37–48.

64. Shah D, Romero F, Duong M, Wang N, Paudyal B, Suratt BT, et al. Obesity-induced adipokine imbalance impairs mouse pulmonary vascular endothelial function and primes the lung for injury. *Sci. Rep*. (2015) 5:11362. doi: 10.1038/srep11362

65. Hamilton BS, Paglia D, Kwan AY, Deitel M, Cydulka RK, Yoon KJ, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N Engl J Med*. (1996) 334:292–5. doi: 10.1056/NEJM199602103340503

66. Richard KA, Morales-Nebreda L, Soberanes S, Nicholson T, Ngdheloug R, Cho T, et al. Impaired clearance of influenza A virus in obese, leptin receptor deficient mice is independent of leptin signaling in the lung epithelium and macrophages. *PLoS ONE*. (2014) 9:e108138. doi: 10.1371/journal.pone.0108138

67. Smith AG, Sheridan PA, Tseng RI, Sheridan JF, Beck MA. Selective impairment in dendritic cell function and altered antigen-specific CD8+ T-cell responses in diet-induced obese mice infected with influenza virus. *Immunology*. (2009) 126:268–79. doi: 10.1111/j.1365-2667.2008.02895.x

68. Zhang AJ, To KK, Li C, Lau CC, Poon VK, Chan CC, et al. Leptin mediates the pathogenesis of severe 2009 pandemic influenza A(H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity. *J Infect Dis*. (2013) 207:1270–80. doi: 10.1093/infdis/jit031

69. Khan SH, Hemann EA, Legle KL, Norian LA, Badovinac VP. Diet-induced obesity does not impact the generation and maintenance of primary memory CD8+ T cells. *J Immunol*. (2014) 193:5873–82. doi: 10.4049/jimmunol.1401685
Obesity impairs the adaptive immune response to influenza virus infection. Nat Rev Immunol. (2012) 12:295–305. doi: 10.1038/nri3166

Manicone AM, Gong K, Johnston LK, Giannandrea M. Diet-induced obesity alters myeloid cell populations in naive and infected lung. Respir Res. (2016) 17:24. doi: 10.1186/s12931-016-0341-8

Cheung KP, Taylor KR, Jameson JM. Immunomodulation at epithelial sites by obesity and metabolic disease. Immunol Res. (2012) 52:182–99. doi: 10.1007/s12026-011-8261-7.

Green WD, Beck MA. Obesity impairs the adaptive immune response to influenza virus. Am Am Thorac Soc. (2017) 14(Suppl. 5):S406–9. doi: 10.1513/AnnalsATS.201706-447AW

Kosaraju R, Guesdon W, Crouch MJ, Teague HL, Sullivan EM, Karlsson EA, et al. B Cell activity is impaired in human and mouse obesity and is responsive to an essential fatty acid upon murine influenza infection. J Immunol. (2017) 198:4738–52. doi: 10.4049/jimmunol.1601031.

Rebeles J, Green WD, Alwarawrah Y, Nichols AG, Eisner W, Danzaki K, et al. Obesity-induced changes in T cell metabolism are associated with impaired memory T cell response to influenza and are not reversed with weight loss. J Infect Dis. (2018) 219:1652–61. doi: 10.1093/infdis/jiy700

Lee FY, Li Y, Yang EK, Yang SQ, Lin HZ, Trush MA, et al. Phenotypic abnormalities in macrophages from leptin-deficient, obese mice. Am J Physiol. (1997) 276:C386–394. doi: 10.1152/ajpcell.1997.276.C386

Ahn SY, Sohn SH, Lee SY, Park HL, Park YW, Kim H, et al. The effect of lipopolysaccharide-induced obesity and its chronic inflammation on influenza virus-related pathology. Environ Toxicol Pharmacol. (2015) 40:924–30. doi: 10.1016/j.etap.2015.09.020

Cho WJ, Lee DK, Lee SY, Sohn SH, Park HL, Park YW, et al. Diet-induced obesity reduces the production of influenza vaccine-induced antibodies via impaired macrophage function. Acta Virol. (2016) 60:298–306. doi: 10.4149/av_2016_03_298

Costanzo AE, Taylor KR, Dutt S, Han PP, Fujikawa K, Jameson JM. Obesity impairs gammadelta T cell homeostasis and antiviral function in humans. PLoS ONE. (2015) 10:e0120918. doi: 10.1371/journal.pone.0120918

Maccia L, Delacre M, Abboud G, Ouk TS, Delanoye A, Verwaerde C, et al. Impairment of dendritic cell functionality and steady-state number in obese mice. J Immunol. (2006) 177:5997–6006. doi: 10.4049/jimmunol.177.9.5997

Pizzolla A, Oh DY, Chen Y, Li C, Li C, Chu H, et al. Prostaglandin E2-mediated impairment of innate immune response to A(H1N1)pdm09 infection in diet-induced obese mice could be restored by paracetamol. J Infect Dis. (2019) 219:795–807. doi: 10.1093/infdis/jiy527

Tsiay LY, Liou KH, Gunalan MG, Li N, Lim DS, Fisher DA, et al. Type I IFNs and IL-18 regulate the antiviral response of primary human gammadelta T cells against dendritic cells infected with Dengue virus. J Immunol. (2015) 194:3890–900. doi: 10.4049/jimmunol.1303343

Yang H, Youm YH, Vandannagars B, Rood J, Kumar KG, Butler AA, et al. Obesity accelerates thymic aging. Blood. (2009) 114:3803–12. doi: 10.1182/blood-2009-03-213595

Loftus RM, Finlay DK. Immunometabolism: cellular metabolism turns immune regulator. J Biol Chem. (2016) 291:1–10. doi: 10.1074/jbc.R115.693903

O’Neill LA, Kishon RI, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. (2016) 16:553–65. doi: 10.1038/nri.2016.70.

Touc S, Clement K, Andre S. T cell populations and functions are altered in human obesity and Type 2 diabetes. Curr Diab Rep. (2017) 17:81. doi: 10.1007/s11892-017-0900-5

DeFuria J, Belkina AC, Jagannath-Bogdan M, Snyder-Cappione J, Carr JD, Nersesova YR, et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc Natl Acad Sci USA. (2013) 110:5133–8. doi: 10.1073/pnas.1215480110

Shaikh SR, Haas KM, Beck MA, Teague H. The effects of diet-induced obesity on B cell function. Clin Exp Immunol. (2015) 179:990–9. doi: 10.1111/cei.12444.

Farnsworth CW, Schott EM, Benvie A, Kates SL, Schwarz EM, Gill SR, et al. Exacerbated Staphylococcus aureus. foot infections in obese/diabetic mice are associated with impaired germinal center reactions, Ig class switching, and humoral immunity. J Immunol. (2018) 201:560–72. doi: 10.4049/jimmunol.1800253

Laurin AS, Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. (2010) 6:e1001005. doi: 10.1371/journal.ppat.1001005

Domingo E. RNA virus evolution, population dynamics, and nutritional status. Biol Trace Elem Res. (1997) 56:23–30. doi: 10.1007/BF02778981

Nelson HK, Shi Q, Van Dael P, Schiffirin EJ, Blum S, Barclay D, et al. Host and the seasonal influenza A virus infection. Postgrad Med J. (2010) 86:515–21. doi: 10.1136/pgmj.2009.096206

Wang B, Russell ML, Fonseca K, Earn DJD, Horsman G, Van Caeseele P, et al. Predictors of influenza a molecular viral shedding in Hutterite communities. Influenza Other Respir Viruses. (2017) 11:254–62. doi: 10.1011/irv.12448

Maier HE, Lopez R, Sanchez N, Ng S, Gresh L, Ojeda S, et al. Obesity Increases the Duration of influenza A virus shedding in adults. J Infect Dis. (2018) 218:1378–82. doi: 10.1093/infdis/jiy370

Yan J, Grantham M, Pantelic J, Bueno de Mesquita PJ, Albert B, Liu F, et al. (2018). Influenza viruses in exhaled breath of symptomatic seasonal influenza cases from a college community. Proc Natl Acad Sci USA. 115, 1081–1086. doi: 10.1073/pnas.1716561115
126. Weger-Lucarelli J, Auerswald H, Vignuzzi M, Dussart P, Karlsson EA. Taking a bite out of nutrition and arbovirus infection. PLoS Negl Trop Dis. (2018) 12:e0006247. doi: 10.1371/journal.pntd.0006247

127. Xue KS, Stevens-Ayers T, Campbell AP, Enghrud JA, Pergam SA, Boechk M, et al. Parallel evolution of influenza across multiple spatiotemporal scales. Elife. (2017) 6:e26875. doi: 10.7554/eLife.26875

128. Te Velthuis AJ, Fodor E. Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis. Nat Rev Microbiol. (2016) 14:479–93. doi: 10.1038/nrmicro.2016.87

129. Russell AB, Trapnell C, Bloom JD. Extreme heterogeneity of influenza virus infection in single cells. Elife. (2018) 7:32303. doi: 10.7554/eLife.32303

130. Steuerman Y, Cohen M, Peshes-Yaloz N, Valadarsky L, Cohn O, David A, et al. Increased risk of influenza among vaccinated adults who are obese. Int J Obes. (2017) 41:1324–30. doi: 10.1038/ijo.2017.131

131. Smut MA, Wang HL, Kim E, Barragan N, Aldrovandi GM, El Amin AN, et al. Influenza vaccine is protective against laboratory-confirmed influenza in obese children. Pediatr Infect Dis J. (2016) 35:440–5. doi: 10.1097/INF.0000000000001029

132. Neidich SD, Green WD, Rebeles J, Karlsson EA, Schultz-Cherry S, Noah TL, et al. Dissection of influenza infection in vivo by single-cell RNA sequencing. Cell Syst. (2018) 6:679–691 e674. doi: 10.1016/j.cels.2018.05.008

133. Neidich SD, Green WD, Rebeles J, Karlsson EA, Schultz-Cherry S, Noah TL, et al. Population pharmacokinetics of orally administered oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. Br J Clin Pharmacol. (2016) 81:1103–12. doi: 10.1111/bcp.12892

134. Callahan ST, Wolff M, Hill HR, Edwards KM, Group NVTEUPVHNVS. Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults. J Infect Dis. (2014) 210:1270–4. doi: 10.1093/infdis/jiu245

135. Esposito S, Giavoli C, Trombetta C, Bianchini S, Montinaro V, Spada A, et al. Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children. Vaccine. (2016) 34:56–60. doi: 10.1016/j.vaccine.2015.11.019

136. White SJ, Taylor MJ, Hurt KT, Jensen MD, Poland GA. Leptin-based adjuvants: an innovative approach to improve vaccine response. Vaccine. (2013) 31:1666–72. doi: 10.1016/j.vaccine.2013.01.032

137. Alti D, Sambamurthy C, Kalangi SK. Emergence of leptin in infection and immunity: scope and challenges in vaccines formulation. Front Cell Infect Microbiol. (2018) 8:147. doi: 10.3389/fcimb.2018.00147

138. Esposito S, Giavoli C, Trombetta C, Bianchini S, Montinaro V, Spada A, et al. Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children. Vaccine. (2016) 34:56–60. doi: 10.1016/j.vaccine.2015.11.019

139. Shin WJ, Seong BL. Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains. Expert Opin Drug Discov. (2019) 14:153–68. doi: 10.1080/17464491.2019.1560261

140. Lehnert R, Plets M, Reuss A, Schaberg T. Antiviral Medications in Seasonal and Pandemic Influenza. Dtsch Arztebl Int. (2016) 113:799–807. doi: 10.3238/arztebl.2016.0799

141. Segaloff HE, Evans R, Arshad S, Zervos MJ, Archer C, Kaye KS, et al. The impact of obesity and timely antiviral administration on severe influenza outcomes among hospitalized adults. J Med Virol. (2018) 90:212–8. doi: 10.1002/jmv.24946

142. Jefferson T, Jones MA, Doshi P, Del Mar CR, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. (2014) 4:CD008965. doi: 10.1002/14651858.CD008965.pub4

143. Jittamala P, Pukrittayakamee S, Tarning J, Lindegardh N, Hanpithakpong W, Taylor WR, et al. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects. Antimicrob Agents Chemother. (2014) 58:1615–21. doi: 10.1128/AAC.01786-13

144. Chairat K, Jittamala P, Hanpithakpong W, Day NP, White NJ, Pukrittayakamee S, et al. Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. Br J Clin Pharmacol. (2016) 81:1103–12. doi: 10.1111/bcp.12892

145. Ariano RE, Sitar DS, Zelenitsky SA, Zarychanski R, Pisipati A, Ahern S, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy children. Cochrane Database Syst Rev. (2014) 4:CD008965. doi: 10.1002/14651858.CD008965.pub4

146. Alti D, Sambamurthy C, Kalangi SK. Emergence of leptin in infection and immunity: scope and challenges in vaccines formulation. Front Cell Infect Microbiol. (2018) 8:147. doi: 10.3389/fcimb.2018.00147

147. Jittamala P, Pukrittayakamee S, Tarning J, Lindegardh N, Hanpithakpong W, Taylor WR, et al. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects. Antimicrob Agents Chemother. (2014) 58:1615–21. doi: 10.1128/AAC.01786-13

148. Chairat K, Jittamala P, Hanpithakpong W, Day NP, White NJ, Pukrittayakamee S, et al. Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. Br J Clin Pharmacol. (2016) 81:1103–12. doi: 10.1111/bcp.12892

149. Ariano RE, Sitar DS, Zelenitsky SA, Zarychanski R, Pisipati A, Ahern S, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy children. Cochrane Database Syst Rev. (2014) 4:CD008965. doi: 10.1002/14651858.CD008965.pub4

150. Alti D, Sambamurthy C, Kalangi SK. Emergence of leptin in infection and immunity: scope and challenges in vaccines formulation. Front Cell Infect Microbiol. (2018) 8:147. doi: 10.3389/fcimb.2018.00147

151. Jittamala P, Pukrittayakamee S, Tarning J, Lindegardh N, Hanpithakpong W, Taylor WR, et al. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects. Antimicrob Agents Chemother. (2014) 58:1615–21. doi: 10.1128/AAC.01786-13

152. Chairat K, Jittamala P, Hanpithakpong W, Day NP, White NJ, Pukrittayakamee S, et al. Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. Br J Clin Pharmacol. (2016) 81:1103–12. doi: 10.1111/bcp.12892

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Honce and Schultz-Cherry. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.